ERBB2 and breast carcinoma: The INFORM trial, a randomized phase II study, compared cisplatin and doxorubicin-cyclophosphamide in BRCA 1/2 carriers with HER2-negative breast cancer and found no significant difference in pCR or RCB 0/1 between the two arms [43].